



Noncoding RNAs as Players, Biomarkers and Targets in Diabetes

Guest Editor:

Dr. Ari Meerson

1. Principal Investigator at MIGAL
- Galilee Research Institute, Kiryat
Shmona, Israel
2. Lecturer at Tel Hai Academic
College, Qiryat Shmona, Israel
3. Visiting Researcher at the
Department of Biomedical
Sciences, University of
Copenhagen, Copenhagen,
Denmark

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editor

Dear Colleagues,

Noncoding RNAs (such as microRNAs, lncRNAs and circular RNAs) have a variety of functions in normal physiology, and take part in the regulatory mechanisms which are deregulated in metabolic disease. Their specific profiles in body fluids, such as plasma and serum, has led to the search for RNA-based biomarkers of disease, in particular diabetes and its co-morbidities. Additionally, the relative ease of manipulation of their function, e.g., by means of complementary oligonucleotides, has underscored their potential as therapeutic targets. In this Special Issue of *Diabetology*, we invite researchers to submit original research or review articles focusing on the various classes of ncRNAs as mechanistic effectors, biomarkers and/ or therapeutic targets in diabetes and/or its co-morbidities.

Dr. Ari Meerson
Guest Editor

